Management of High PVC Burden with Sharp Chest Pain

Risk Assessment

A PVC burden of 14.9-19% significantly exceeds the threshold (>10-15%) associated with development of PVC-induced cardiomyopathy, placing the patient at high risk for left ventricular dysfunction 1
PVC burden ≥24% is independently associated with cardiomyopathy, but even burdens >10% can result in cardiomyopathy, making this 14.9-19% burden clinically significant 1

Catheter ablation should be considered as the primary treatment approach for patients with high PVC burden (14.9-19%) and risk of developing PVC-induced cardiomyopathy, as recommended by the European Society of Cardiology 1, 2
The American College of Cardiology recommends catheter ablation for patients with symptomatic PVCs, with success rates of up to 80% and normalization of left ventricular ejection fraction within 6 months in 82% of patients with depressed ventricular function 1
Beta-blockers should be initiated as first-line medical therapy for patients with high PVC burden, as recommended by the European Society of Cardiology 3
The European Society of Cardiology recommends amiodarone for patients with frequent symptomatic PVCs or PVCs associated with left ventricular dysfunction 3

Echocardiography should be performed to assess left ventricular function and evidence of cardiomyopathy, as recommended by the American College of Cardiology 1, 4
Cardiac MRI may be considered to exclude underlying structural heart disease and identify potential arrhythmogenic substrate, as recommended by the American College of Cardiology 4
Exercise stress test should be performed to evaluate response of PVCs to exercise and presence of ischemia, as recommended by the American College of Cardiology 4

Repeat Holter monitoring should be performed to assess reduction in PVC burden and guide further management decisions, as recommended by the European Society of Cardiology 1
Serial echocardiography should be performed to monitor for development or improvement of cardiomyopathy and assess left ventricular function, as recommended by the European Society of Cardiology 1

PVC characteristics should be analyzed to determine PVC morphology and likely origin, with the right ventricular outflow tract being the most common origin at 52%, as reported by the European Society of Cardiology 1
QRS duration (>160 ms) may suggest arrhythmogenic right ventricular cardiomyopathy, as reported by the American College of Cardiology 4

Delaying treatment in patients with high PVC burden (>15%) even if symptoms are intermittent, as they remain at risk for developing cardiomyopathy, as warned by the European Society of Cardiology 1
Using class I antiarrhythmic drugs as first-line therapy, especially if there is any evidence of structural heart disease or reduced ejection fraction, as warned by the European Society of Cardiology 3
Failing to monitor left ventricular function in patients with high PVC burden, even after successful treatment, as warned by the European Society of Cardiology 1
Overlooking the possibility that PVCs may be a manifestation of underlying coronary artery disease, especially given sharp chest pain, as reported by the European Heart Journal 5